array(3) { ["company_details"]=> array(13) { ["name"]=> string(14) "ELEKTA LIMITED" ["slug"]=> string(23) "dbe4b-gb-elekta-limited" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/03cdfb0f-1bfc-426b-afae-aad1f451dee7" ["description"]=> string(735) "At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm. Visit elekta.com to learn more." ["address_street"]=> string(11) "Linac House" ["address_place"]=> string(7) "CRAWLEY" ["address_region"]=> NULL ["founding_date"]=> string(10) "1996-09-02" ["website_domain"]=> string(10) "elekta.com" ["website_url"]=> string(22) "https://www.elekta.com" ["industry_codes"]=> array(1) { [0]=> string(46) "Surgical and Medical Instruments and Apparatus" } ["employee_count"]=> int(820) ["article_count"]=> int(550) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(30) "Worse than expected for Elekta" ["snippet_en"]=> string(141) "Radiation therapy company Elekta reports an operating profit of SEK 485 million for the third quarter of the company's broken financial year." ["url"]=> string(82) "https://www.privataaffarer.se/placeringar/aktier/samre-an-vantat-for-elekta-Wi5O2/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/49e7e114-bde6-4a86-9816-9a19f8cab1a7" ["source"]=> string(17) "privataaffarer.se" ["publication_date"]=> string(10) "2024-02-29" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(18) "Financial Distress" } } [1]=> array(7) { ["title_en"]=> string(57) "Elekta's adjusted operating profit was below expectations" ["snippet_en"]=> string(108) "The medical technology company Elekta reports a turnover in line with expectations during the third quarter." ["url"]=> string(86) "https://www.affarsvarlden.se/artikel/elektas-justerade-rorelseresultat-under-forvantan" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b4758a82-1908-4f9f-b35f-13b3f887b1af" ["source"]=> string(16) "affarsvarlden.se" ["publication_date"]=> string(10) "2023-12-30" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } [2]=> array(7) { ["title_en"]=> string(56) "ELEKTA: TRACES SLOWDOWN IN CHINA IN COMING QUARTER - CEO" ["snippet_en"]=> string(170) "STOCKHOLM (Nyhetsbyrån Direkt) Radiation therapy system company Elekta expects a slowdown in China in the coming quarters. In the longer term, however, Elekta is posi..." ["url"]=> string(93) "https://tradevenue.se/artiklar/elekta-spar-inbromsning-i-kina-under-kommande-kvartal-vd-19161" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1c51a464-5c35-4e3e-8731-90509e2b66e7" ["source"]=> string(13) "tradevenue.se" ["publication_date"]=> string(10) "2023-08-24" ["categories"]=> array(1) { [0]=> string(31) "Financial Update/Profit Warning" } } [3]=> array(7) { ["title_en"]=> string(34) "Elekta crushes profit expectations" ["snippet_en"]=> string(160) "Radiation therapy company Elekta reports an adjusted operating profit of SEK 427 million for the first quarter of the company's broken financial year 2023/2024." ["url"]=> string(85) "https://www.privataaffarer.se/placeringar/aktier/elekta-krossar-vinstforvantningarna/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d846e1af-d7c3-4c5c-9fd4-6d85f1597b1a" ["source"]=> string(17) "privataaffarer.se" ["publication_date"]=> string(10) "2023-08-24" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(12) "Restatements" } } [4]=> array(7) { ["title_en"]=> string(27) "Results crusher from Elekta" ["snippet_en"]=> string(253) "The medical technology company Elekta reports an interim report for the first quarter of the broken fiscal year 2023/2024 that beats analysts' expectations, especially around the adjusted operating profit. Net profit increased sharply during the period." ["url"]=> string(62) "https://www.aktiespararna.se/nyheter/resultatkross-fran-elekta" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f13f624b-e6c4-4377-9261-5930dbf55209" ["source"]=> string(16) "aktiespararna.se" ["publication_date"]=> string(10) "2023-08-24" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } [5]=> array(7) { ["title_en"]=> string(38) "Elekta shatters expectations – again" ["snippet_en"]=> string(115) "Elekta's report exceeded expectations. The profit increases sharply and the stock continues to be considered a buy." ["url"]=> string(61) "https://www.di.se/analys/elekta-krossar-forvantningarna-igen/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2a6e4b50-3a64-4eed-adbb-6b62faefe5f9" ["source"]=> string(5) "di.se" ["publication_date"]=> string(10) "2023-08-24" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(42) "Elektra competitor Viewray warns of profit" ["snippet_en"]=> string(190) "American Viewray, which has been described as the only competitor to the Swedish radiation therapy company Elekta in the area of ​​MR-guided radiation treatment systems, warns of profit." ["url"]=> string(64) "https://www.di.se/live/elektra-konkurrenten-viewray-vinstvarnar/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d78a01c0-8cb1-48cd-842e-d8bf09c927d9" ["source"]=> string(5) "di.se" ["publication_date"]=> string(10) "2023-04-13" ["categories"]=> array(1) { [0]=> string(31) "Financial Update/Profit Warning" } } [7]=> array(7) { ["title_en"]=> string(75) "Elekta's report in line with the profit warning – pressured by currencies" ["snippet_en"]=> string(221) "Radiation therapy company Elekta, which issued a profit warning earlier in November, presents an ebita result for the second quarter of the broken fiscal year of SEK 539m, corresponding to an ebita margin of 14.5 percent." ["url"]=> string(85) "https://www.di.se/live/elektas-rapport-i-linje-med-vinstvarningen-pressas-av-valutor/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/736b772a-72c4-42f6-8703-9563764e78a8" ["source"]=> string(5) "di.se" ["publication_date"]=> string(10) "2019-11-28" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(18) "Ecological Impacts" } } [8]=> array(7) { ["title_en"]=> string(37) "Interim report, May–January 2019/20" ["snippet_en"]=> string(252) "Interim report, May–January 2019/20 Outlook maintained for the full year - weak quarter We delivered an improved EBITA margin that benefited from good sales in Neuro and Oncology Informatics as well as our cost reduction program. But from the outside" ["url"]=> string(87) "https://www.elekta.com/pressreleases/3E964F550065CF3B/delarsrapport-maj-januari-2019-20" ["image_url"]=> string(78) "https://images.businessradar.com/articles/34f078a5-3f40-4b66-8009-2faa5b0a3706" ["source"]=> string(10) "elekta.com" ["publication_date"]=> string(10) "2019-01-01" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(35) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(25) } [2]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(23) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(19) } [4]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(16) } [5]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(16) } [6]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(15) } [7]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(14) } [8]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(11) } [9]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(11) } [10]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(11) } [11]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(9) } [12]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(8) } [13]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(7) } [14]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(6) } [15]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(6) } [16]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(6) } [17]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(6) } [18]=> array(2) { ["name"]=> string(25) "Leadership and Governance" ["count"]=> int(5) } [19]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(5) } [20]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(5) } [21]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(4) } [22]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(4) } [23]=> array(2) { ["name"]=> string(12) "Staff hiring" ["count"]=> int(4) } [24]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(4) } [25]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(3) } [26]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(3) } [27]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(3) } [28]=> array(2) { ["name"]=> string(20) "Corporate Governance" ["count"]=> int(2) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(2) } } } dbe4b-gb-elekta-limited